louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03651882: Oxytocin i.m./i.v. Versus Carbetocin i.v. in Elective Cesarean Sections
Official title: Intramyometrial and Intravenous Oxytocin Compared to Intravenous Carbetocin for Prevention of Postpartum Hemorrhage in Elective Cesarean Sections - a Monocentric Randomized Controlled Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Postpartum Hemorrhage
Lead sponsor: University of Zurich
Sponsor class: OTHER
First posted: 2018-08-29
Enrollment: 550
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Before c-section the patients will be randomized to the oxytocin or the carbetocin group.
Primary purpose: PREVENTION

Brief summary: Objective is to proof non-inferiority of intramyometrial and intravenous oxytocin application compared to intravenous carbetocin for prevention of postpartum hemorrhage in planned, uncomplicated cesarean deliveries.


Eligibility criteria: Inclusion Criteria:

* elective cesarean section
* present informed consent
* completed 36 weeks of gestation

Exclusion Criteria:

* need for intubation (carbetocin is only licensed for epidural or spinal anesthesia)
* multiple fetus pregnancy
* known coagulopathy
* Placenta praevia
* morbidly adherent placenta
* placental abruption
* thrombocyte dysfunction
* HELLP-syndrome
* preeclampsia
* history of uterine atony

Primary outcomes:
measure: incidence of women with a delta hemoglobin ≥ 30g/l.
timeFrame: 48 hours
Secondary outcomes:
measure: adverse maternal outcome parameters
timeFrame: 15 days
measure: adverse maternal outcome parameters
timeFrame: 15 days
measure: adverse maternal outcome parameters
timeFrame: 15 days
measure: adverse maternal outcome parameters
timeFrame: 15 days
measure: adverse maternal outcome parameters
timeFrame: 15 days
measure: adverse maternal outcome parameters
timeFrame: 15-300 minutes
measure: adverse maternal outcome parameters
timeFrame: 15 days
measure: adverse maternal outcome parameters
timeFrame: 15 days
Other outcomes:
Locations:
city: Zürich
country: Switzerland
facility: University Hospital Zurich
Study officials:
affiliation: University of Zurich
name: Christian Haslinger, M.D.
role: STUDY_CHAIR
References:
Clinical trial NCT04658082: A Pilot Trial of the Non-invasive H.G.R Glucometer
Official title: A Pilot Trial to Evaluate the Precision and Accuracy of the Non-invasive H.G.R Glucometer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Type 2 Diabetes
Lead sponsor: Sheba Medical Center
Sponsor class: OTHER_GOV
First posted: 2020-12-08
Enrollment: 5
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: A pilot study evaluating the accuracy of a non-invasive glucose monitor (GWave) with venous glucose measured by core laboratory during a glucose tolerance test (GTT) in patients with type 2 diabetes.

The study is conducted on 5 subjects undergoing a 75gr GTT, with blood glucose measured at baseline and at 8 time points up to 180 minutes post glucose ingestion both by GWave non-invasive glucometer and by core lab glucose measurement.


Eligibility criteria: Inclusion Criteria:

1. Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
2. Male or female.
3. Age above or equal to 18 years at the time of signing informed consent.
4. Diagnosed with type 2 diabetes mellitus ≥ 180 days before screening.
5. HbA1c of 6.0-8.0% .

Exclusion Criteria:

1. Participants under the age of 18 years
2. pregnant women or patients with normal blood glucose.

Primary outcomes:
measure: difference between core lab and non invasive glucose measurements
timeFrame: 3 HOURS
Secondary outcomes:
Other outcomes:
Locations:
city: Tel-Hashomer
country: Israel
facility: Sheba Medical Center
Study officials:
affiliation: Sheba Medical Center
name: Amir Tirosh, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01452620: Endovascular Abdominal Aortic Aneurysm Repair by Interventional Cardiologists
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Endovascular Abdominal Aortic Aneurysm Repair (EVAR)
Keywords: Endovascular Abdominal Aortic Aneurysm Repair (EVAR)
Abdominal Aortic aneurysm (AAA)
Lead sponsor: St. Joseph Mercy Oakland Hospital
Sponsor class: OTHER
First posted: 2011-10-17
Enrollment: 170
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Study patients comprised of all patients undergoing endovascular abdominal aortic aneurysm repair performed primarily by Interventional Cardiologists in our community setting.

Brief summary: Registry for Endovascular repair of abdominal aortic aneurysm performed primarily by Interventional Cardiologists


Eligibility criteria: Inclusion Criteria:

* Patients with abdominal aortic aneurysm amenable for endovascular repair

Exclusion Criteria:

* Pregnant patients
* Patients less than 18 years old.

Primary outcomes:
measure: Mortality
timeFrame: mean follow up, 30 months
Secondary outcomes:
measure: Complications
timeFrame: mean follow up, 30 months
Other outcomes:
Locations:
city: Pontiac
country: United States
facility: St. Joseph Mercy Oakland Hospital
state: Michigan
Study officials:
affiliation: St. Joseph Mercy Oakland Hospital
name: Abhijeet Basoor, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: St. Joseph Mercy Oakland Hospital
name: Kiritkumar Patel, MD
role: STUDY_DIRECTOR
affiliation: St. Joseph Mercy Oakland Hospital
name: Abdul R Halabi, MD
role: STUDY_DIRECTOR
affiliation: St. Joseph Mercy Oakland Hospital
name: Nishit Choksi, MD
role: STUDY_DIRECTOR
affiliation: St. Joseph Mercy Oakland Hospital
name: Thanh Phan, MD
role: STUDY_DIRECTOR
affiliation: St. Joseph Mercy Oakland Hospital
name: Michele DeGregorio, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT00680420: DNA Microarray Study of Pancreas Cancer
Official title: DNA Microarray Analysis of Endoscopic Ultrasound-Guided Fine Needle Aspiration Biopsies to Discriminate Benign From Malignant Pancreatic Lesions
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pancreas Cancer
Keywords: pancreas cancer
pancreas cyst
DNA microarray
Lead sponsor: Oregon Health and Science University
Sponsor class: OTHER
First posted: 2008-05-20
Enrollment: 27
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients with suspected pancreas mass

Brief summary: Pancreas cancer and precancerous cysts can be difficult to diagnose. Sometimes biopsies do not show cancer when cancer is actually present. We hypothesize that genetic differences exist in tissue that is malignant compared to nonmalignant. When patients present with a pancreas mass or cyst, we biopsy it by fine-needle aspiration during upper endoscopy with ultrasound guidance. We would like to use tissue obtained via endoscopic ultrasound guided fine needle aspiration to perform DNA microarray analysis, and compare the differences in gene expression level in the benign tissue compared to cancerous tissue in order to improve our diagnostic capabilities. DNA microarray measures gene expression level rather than germline mutations. The true diagnosis will be based on cytology, surgical pathology, or clinical followup. The performance of the microarray test as a diagnostic test will be compared to the performance of cytology.


Eligibility criteria: Inclusion Criteria:

* Adults aged 18 or older who are able to give informed consent who present for an endoscopic ultrasound to evaluate a pancreas mass or cyst or for suspicion of cancer.

Exclusion Criteria:

* Unable to give informed consent, pregnant or nursing, contraindication to endoscopic ultrasound, no mass or cyst found on ultrasound

Primary outcomes:
measure: Gene expression profile is 95% accurate in diagnosis of malignancy
timeFrame: after enrollment of 50 patients
Secondary outcomes:
Other outcomes:
Locations:
city: Portland
country: United States
facility: Oregon Health and Science University
state: Oregon
Study officials:
affiliation: Oregon Health and Science University
name: Sarah Rodriguez, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05025020: Use of an Interactive 3D Tool During Consultation for Breast Reconstruction Surgery
Official title: Incorporating Three-Dimensional Visualization in Breast Reconstruction Consultation
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Breast Cancer
Keywords: Reconstruction Surgery
Interactive 3D Tool
Consultation
21-318
Lead sponsor: Memorial Sloan Kettering Cancer Center
Sponsor class: OTHER
First posted: 2021-08-27
Enrollment: 88
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this study is to find out whether using an interactive 3D tool during a standard surgical consultation can lead to greater patient satisfaction with the information provided about breast reconstruction options than the standard consultation alone. The study researchers will also assess whether women whose surgical consultation includes the use of the 3D tool are more satisfied with their breasts and with the decisions they made about their reconstruction procedure.


Eligibility criteria: Inclusion Criteria:

* ≥18 years old
* Presenting at MSK for initial breast reconstruction consultation
* Planning to undergo mastectomy at time of consultation
* English spoken as primary language
* Able to provide informed consent without a legally authorized representative

Exclusion Criteria:

* Prior breast reconstruction
* Prior breast reconstruction consultation with a plastic surgeon

Primary outcomes:
measure: BREAST-Q Satisfaction
timeFrame: 4 weeks
Secondary outcomes:
measure: BREAST-Q Satisfaction
timeFrame: 3 months after surgery
Other outcomes:
Locations:
city: New York
country: United States
facility: Memorial Sloan Kettering Cancer Center (All Protocol Activities)
state: New York
Study officials:
affiliation: Memorial Sloan Kettering Cancer Center
name: Carrie Stern, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00442520: Pharmacogenomic Study in Patients of Lung, Colorectal and Head/Neck Cancers Receiving Chemotherapy
Official title: Pharmacogenomic Study in Patients of Lung, Colorectal and Head/Neck Cancers Receiving Chemotherapy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Lung Cancer
Colorectal Cancer
Head and Neck Cancer
Lead sponsor: University of Kansas Medical Center
Sponsor class: OTHER
Collaborators: name: Paul J. Patton Trust
First posted: 2007-03-02
Enrollment: 70
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: medical center

Brief summary: The purpose of this study is to look at several genes that might determine how the body processes the drugs used to treat lung, colorectal and head and neck cancers. The goal of this examination is to help investigators determine the proper dosage to give future cancer patients or to better predict which future patients will respond to particular drug therapies.

Detailed description: This study is to establish a pilot pharmacogenomic program in identifying genetic variation to predict the safety, toxicity and/or efficacy of drugs. DNA will be extracted from patients' peripheral blood to study SNPs in DPD, TS, MTHFR, UGT1A1, CYP3A4, CYP3A5, GSTM1, GSTT1, GSTP1, HO-1, ERCC1, XPD, XRCC1 and EGFR genes. The results of genetic study will be compared to treatment efficacy and toxicity. The ultimate goal is to use genotype profiles to provide individualized cancer treatment to improve outcome and decrease toxicity.

Eligibility criteria: Inclusion Criteria:

* Lung, Colorectal and Head and Neck Cancer Patients that have received or plan to receive chemotherapy as part of their treatment

Exclusion Criteria:

* Colorectal cancer patients that have never received or will not receive chemotherapy as part of their therapy
* Head and Neck cancer patients that have never received or will not receive chemotherapy as part of their treatment
* Patients with cancer types other than colorectal or head and neck
* Unable to give informed consent

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Kansas City
country: United States
facility: University of Kansas Medical Center
state: Kansas
Study officials:
affiliation: University of Kansas Medical Center
name: Yu-Jui Yvonne Wan, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06141720: Feasibility of a Mindfulness Intervention for Endometriosis Surgery
Official title: Feasibility of a Mindfulness Intervention for Endometriosis Surgery
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Endometriosis
Pain
Mindfulness
Lead sponsor: Milton S. Hershey Medical Center
Sponsor class: OTHER
First posted: 2023-11-21
Enrollment: 20
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: Endometriosis is a common cause of pelvic pain in women which has been historically under-studied and under-diagnosed. The goal of this research is to pilot-test the feasibility and acceptability of a manualized, single-session brief mindfulness-based intervention (BMBI) among participants with endometriosis-related chronic pelvic pain (ECPP) who undergo surgical treatment, and gather preliminary data necessary for future studies assessing BMBI's impact on outcomes in surgically-treated ECPP. This pilot study will enroll 10-20 adult participants with ECPP to receive either a BMBI adjunctive to treatment as usual (TAU; n=5-10) or education with TAU (n=5-10) prior to their ECPP surgery. The central hypothesis is the BMBI is feasible to deliver pre-operatively, acceptable to patients, and may help improve acute post-surgical outcomes through more adaptive stress coping and pain processing, enabled by mindfulness training.


Eligibility criteria: Inclusion Criteria:

1. age 18 years or older
2. diagnosis or probable diagnosis of endometriosis
3. candidate for surgical procedure for endometriosis
4. English speaking
5. have access to wifi and email

Exclusion Criteria:

1. prior formal mindfulness training
2. Unable to consent

Primary outcomes:
measure: Use of opioid medication
timeFrame: 1 week
measure: Use of opioid medication
timeFrame: 3 months
measure: Pain intensity
timeFrame: 1 week
measure: Pain intensity
timeFrame: 3 months
Secondary outcomes:
measure: Sleep quality (sleep duration, awakenings, efficiency)
timeFrame: 1 week prior to surgery
measure: Sleep quality (sleep duration, awakenings, efficiency)
timeFrame: 1 week following surgery
measure: Sleep report
timeFrame: 1 week following surgery
measure: Sleep report
timeFrame: 1 week prior to surgery
measure: Emotional functioning
timeFrame: baseline
measure: Emotional functioning
timeFrame: 1 week
measure: Emotional functioning
timeFrame: 3 months
measure: Patient global impression of change
timeFrame: 3 months
measure: Patient global impression of change
timeFrame: 1 week
measure: Pain catastrophizing
timeFrame: baseline
measure: Pain catastrophizing
timeFrame: 1 week
measure: Pain catastrophizing
timeFrame: 3 months
measure: Treatment satisfaction
timeFrame: 1 week
measure: Treatment satisfaction
timeFrame: 3 months
Other outcomes:
Locations:
city: Hershey
country: United States
facility: Penn State Health
state: Pennsylvania
Study officials:
affiliation: Penn State Health
name: Christa Coleman
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03645720: The Prognosis of Graft Using Plastic Cannula in Hemodialysis
Official title: A Prospective Study of the Prognosis of Graft With Plastic Cannula in Hemodialysis
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: End Stage Renal Failure on Dialysis
Lead sponsor: Hallym University Medical Center
Sponsor class: OTHER
First posted: 2018-08-24
Enrollment: 0
Sex: ALL
Minimum age (years): 20
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Parallel Assignment
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the complication of the puncture related complication in AVG (arteriovenous graft) such as pseudoaneurysm and hematoma, and the dialysis adequacy using plastic cannula versus metal needle in hemodialysis patients

Detailed description: 1. Ultrasonography is performed to determine the maturity of vascular access 4 weeks after AVG creation.
2. The first puncture is performed with plastic cannula or metal needle when it is judged that the blood vessel has matured.
3. Four skilled nurses perform vascular access puncture with plastic or metal needle
4. Ultrasound are used to evaluate and record the complications related to the puncture in plastic or metal needle group every month.
5. Complications and dialysis adequacy between the two groups will be evaluated after 6 months

Eligibility criteria: Inclusion Criteria:

* Patients receiving hemodialysis treatment using AVG

Exclusion Criteria:

* Age under 20 years old or over 75 years old
* Abnormal skin condition using immunosuppressants such as steroids.
* Skin disorder
* Metal allergy

Primary outcomes:
measure: Incidence of pseudoaneurysm
timeFrame: Incidence of pseudoaneurysm at 6 months
Secondary outcomes:
measure: punctutre related complication
timeFrame: Monthly for 6 months.
measure: Dialysis adeqaucy
timeFrame: Monthly for 6 months.
Other outcomes:
Locations:
city: Anyang si
country: Korea, Republic of
facility: Hallym University Sacred Heart Hospital
state: Gyeonggi-do
Study officials:
affiliation: Hallym University Medical Center
name: Sun Ryoung Choi, MD,PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06536920: Migraine Among Sohag University Students
Official title: Frequency and Impact of Migraine Among Sohag University Students
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Migraine
Lead sponsor: Sohag University
Sponsor class: OTHER
First posted: 2024-08-05
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Maximum age (years): 25
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CROSSOVER
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Sohag university students

Brief summary: Diagnosis of migraine among students and detect frequency among them and detect how far migraine affect their life


Eligibility criteria: Inclusion Criteria:

* Age from 18 to 25 years old.
* students accept to give informed consent

Exclusion Criteria:

* Students refused to give informed consent
* Age less than 18 or more than 25 ears old.

Primary outcomes:
measure: Migraine screening questionnaire
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Sohag
country: Egypt
facility: Sohag university hospital
Study officials:
References:
Clinical trial NCT06757920: "Bronchoscopic Argon Plasma Coagulation for Managing Endobronchial Carcinoid Lesions
Official title: The Use of Bronchoscopic Argon Plasma Coagulation in Endobronchial Carcinoid
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: NA
Conditions: Endobronchial Carcinoid
Keywords: Argon Plasma Coagulation
fiberoptic bronchoscopy
endobronchial carcinoid
Lead sponsor: Alexandria University
Sponsor class: OTHER
First posted: 2025-01-03
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Argon Plasma Coagulation via non contact probe for debulking and fulgration of the endobronchial carcinoid using fiberoptic bronchoscopy
Primary purpose: TREATMENT

Brief summary: A small tube will go through the respiratory tract and a non contact cauterization will be done to the inside tumor

Detailed description: fiberoptic bronchoscopy will go through the tracheobronchial tree and after localization of the tumor, argon plasma coagulation by initiation non contact electrocautery will be done to the tumor

Eligibility criteria: Inclusion Criteria:

1 - Cooperative patient with written informed consent. 2- Patients diagnosed with endobronchial carcinoid. 3- Patients fit for fiberoptic bronchoscopy. 4- Patients unwilling or unfit for surgery.

Exclusion Criteria:

1 -Poor karnofsky score. 2- Patients unwilling or unfit for bronchoscopy. 3- Extraluminal lesion. 4- Patients with pacemaker. 5- Forced expiratory volume 1 is less than one litre.

Primary outcomes:
measure: Dyspnea Borg Scale
timeFrame: one month
Secondary outcomes:
Other outcomes:
Locations:
city: Alexandria
country: Egypt
facility: Chest Department -Faculty of Medicine
state: Azarita
Study officials:
affiliation: Alexandria University
name: mohamed sabry eltarhony, lecturer
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00931320: Investigation Into the RAtio of LDL-CHolestEroL to HDL-Cholesterol Improvement After Statin Treatment in Korean Patients
Official title: Investigation Into the RAtio of LDL-CHolestEroL to HDL-Cholesterol Improvement After Statin Treatment in Korean Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Dyslipidemias
Keywords: Ratio improvement
LDL-C
HDL-C
Ratio of Low Density Lipoprotein Cholesterol to High Density Lipoprotein Cholesterol Improvement
High Density Lipoprotein Cholesterol
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2009-07-02
Enrollment: 3000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Who have at least made 1 visit to the outpatient clinic within previous 6 months .

Brief summary: An observational, non-interventional, multi-centre study to provide further information on the ratio of LDL-C to HDL-C improvement after statin treatment in Korean patients group.


Eligibility criteria: Inclusion Criteria:

* Subjects who are taking lipid-lowering medication after diagnosed as dyslipidaemia
* Subjects who have at least made 1 visit to the outpatient clinic within previous 6 months
* Subjects who have records of both LDL-C and HDL-C before \& after statin treatment (at least four weeks after statin taking)

Exclusion Criteria:

* Subjects who are unwilling or unable to provide their examination and lab result of medical chart.

Primary outcomes:
measure: Evaluate current LDL/HDL ratio in Korean patients (between baseline & after treatment)
timeFrame: After Treatment : at least 4 weeks before statin taking /Baseline : no limitation.
Secondary outcomes:
measure: Evaluate difference of LDL/HDL ratio among different statins & dosages (between baseline & after treatment)
timeFrame: After Treatment : at least 4 weeks before statin taking / Baseline : no limitation.
Other outcomes:
Locations:
Study officials:
affiliation: AstraZeneca Korea
name: Hyunah Caroline Choi
role: STUDY_DIRECTOR
References: